WO2014087323A2 - Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques - Google Patents

Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques Download PDF

Info

Publication number
WO2014087323A2
WO2014087323A2 PCT/IB2013/060581 IB2013060581W WO2014087323A2 WO 2014087323 A2 WO2014087323 A2 WO 2014087323A2 IB 2013060581 W IB2013060581 W IB 2013060581W WO 2014087323 A2 WO2014087323 A2 WO 2014087323A2
Authority
WO
WIPO (PCT)
Prior art keywords
independently
formula
compound
administration
compositions
Prior art date
Application number
PCT/IB2013/060581
Other languages
English (en)
Other versions
WO2014087323A3 (fr
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014087323A2 publication Critical patent/WO2014087323A2/fr
Publication of WO2014087323A3 publication Critical patent/WO2014087323A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Abstract

L'invention concerne des composés de formule I, de formule II, de formule III et de formule IV ou leurs sels pharmaceutiquement acceptables, ainsi que des polymorphes, des solvates, des énantiomères, des stéréo-isomères et des hydrates de ceux-ci. Les compositions pharmaceutiques comprennent une quantité efficace de composés de formule I, de formule II, de formule III ou de formule IV et des procédés pour le traitement de maladies auto-immunes et métaboliques chroniques peuvent être formulées pour une administration orale, buccale, rectale, topique, transdermique, transmucosale, intraveineuse, parentérale, un sirop ou une injection. De telles compositions peuvent être utilisées pour le traitement de maladies neurodégénératives, de maladies métaboliques, de maladies rénales chroniques et de maladies auto-immunes.
PCT/IB2013/060581 2012-12-06 2013-12-03 Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques WO2014087323A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5091CH2012 2012-12-06
IN5091/CHE/2012 2012-12-06

Publications (2)

Publication Number Publication Date
WO2014087323A2 true WO2014087323A2 (fr) 2014-06-12
WO2014087323A3 WO2014087323A3 (fr) 2014-12-24

Family

ID=50884097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060581 WO2014087323A2 (fr) 2012-12-06 2013-12-03 Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques

Country Status (1)

Country Link
WO (1) WO2014087323A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016051420A1 (fr) * 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
EP3226855A1 (fr) * 2014-12-01 2017-10-11 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
CN111440105A (zh) * 2020-04-01 2020-07-24 南通华山药业有限公司 阿法骨化醇氨基甲酸酯衍生物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131995A1 (fr) * 1983-07-19 1985-01-23 Maggioni-Winthrop S.P.A. Composés à activité hypolipémique
US5120738A (en) * 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
WO2011106688A1 (fr) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Conjugués de bis-acide gras et leurs utilisations
WO2012161798A1 (fr) * 2011-02-25 2012-11-29 Catabasis Pharmaceuticals, Inc. Conjugués d'acide gras et d'acide gamma-aminobutyrique (gaba) et leurs applications
WO2014068463A2 (fr) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions et procédés de traitement d'une inflammation et de troubles métaboliques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131995A1 (fr) * 1983-07-19 1985-01-23 Maggioni-Winthrop S.P.A. Composés à activité hypolipémique
US5120738A (en) * 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
WO2011106688A1 (fr) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Conjugués de bis-acide gras et leurs utilisations
WO2012161798A1 (fr) * 2011-02-25 2012-11-29 Catabasis Pharmaceuticals, Inc. Conjugués d'acide gras et d'acide gamma-aminobutyrique (gaba) et leurs applications
WO2014068463A2 (fr) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions et procédés de traitement d'une inflammation et de troubles métaboliques

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016051420A1 (fr) * 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
CN107207403A (zh) * 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
JP2017531649A (ja) * 2014-09-29 2017-10-26 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014407862B2 (en) * 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3226855A1 (fr) * 2014-12-01 2017-10-11 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
CN111440105A (zh) * 2020-04-01 2020-07-24 南通华山药业有限公司 阿法骨化醇氨基甲酸酯衍生物及其制备方法和用途
CN111440105B (zh) * 2020-04-01 2022-05-17 南通华山药业有限公司 阿法骨化醇氨基甲酸酯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
WO2014087323A3 (fr) 2014-12-24

Similar Documents

Publication Publication Date Title
EP3004049B1 (fr) Compositions et procédés de traitement du diabète et du pré-diabète
WO2014068463A2 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2014087307A2 (fr) Compositions et procédés pour le traitement du syndrome métabolique et du diabète
WO2014087323A2 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2014080307A2 (fr) Compositions et procédés pour le traitement du diabète et du pré-diabète
WO2014106804A2 (fr) Compositions et procédés de traitement du syndrome métabolique et du diabète
WO2014068506A2 (fr) Compositions et procédés pour le traitement de maladies autoimmunes
WO2014195810A2 (fr) Compositions et méthodes pour le traitement du diabète et du prédiabète
US9624168B2 (en) Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) Compositions and methods for the treatment of inflammation and lipid disorders
WO2014068461A2 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
WO2014068459A2 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques
WO2014122575A2 (fr) Conjugués d'acide gras pour le traitement d'inflammations et de maladies métaboliques
WO2014057439A2 (fr) Compositions et procédés de traitement de maladies neurologiques et des complications associées
WO2014053962A2 (fr) Compositions et méthodes de traitement du diabète et du prédiabète
WO2016046679A1 (fr) Compositions et procédés de traitement du diabète et du pré-diabète
WO2015022613A1 (fr) Compositions et méthodes pour le traitement du diabète et du pré-diabète
WO2014083476A2 (fr) Compositions et méthodes pour le traitement de troubles métaboliques et lipidiques
WO2014106805A2 (fr) Conjugués d'acides gras et leurs utilisations
WO2014118649A2 (fr) Compositions et méthodes pour le traitement de maladies cardiovasculaires
US9266823B2 (en) Compositions and methods for the treatment of parkinson's disease
WO2014091465A2 (fr) Compositions et méthodes pour le traitement du syndrome métabolique et de troubles lipidiques
WO2015028956A1 (fr) Compositions et méthodes de traitement de troubles de l'oxydation des acides gras
WO2014080309A2 (fr) Compositions et procédés pour le traitement de troubles inflammatoires et lipidiques
WO2014191885A2 (fr) Compositions et procédés pour le traitement des troubles neuromusculaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13860394

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13860394

Country of ref document: EP

Kind code of ref document: A2